Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20226 (
TATA-binding protein
)
1,297
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BTAF1 (formerly named
TAF(II)170
/
TAF-172
) is an essential, evolutionarily conserved member of the SNF2-like family of ATPase proteins and together with
TATA-binding protein
(
TBP
) forms the B-TFIID complex. BTAF1 has been proposed to play a key role in the dynamic regulation of
TBP
function in RNA polymerase II transcription. We have determined the structure of native B-TFIID purified from human cells by electron microscopy and by image analysis of single particles at a resolution of 28 A. B-TFIID is 15 x 9 nm in size and is organized into a large domain of about 170 kDa, which can be subdivided into two domains. Extending from this domain is a long thumb, which in turn is divided into subdomains of about 25, 15, and 35 kDa, the largest of which is located at the end of the thumb. Immunolabeling experiments localize the extreme carboxyl terminus of BTAF1 within the 170-kDa domain, whereas the amino terminus and
TBP
co-localize to the end of the protruding thumb. The central portion of BTAF1 localizes to the base of the thumb. Comparison of the native B-TFIID with its recombinant form shows that both share a similar domain organization. Collectively, these data provide the first structural model of the B-TFIID complex and map its key functional domains.
...
PMID:Molecular architecture of the basal transcription factor B-TFIID. 1498 2
Transcriptional activity of the
TATA-binding protein
(
TBP
) is controlled by a variety of proteins. The BTAF1 protein (formerly known as
TAF(II)170
/
TAF-172
and the human ortholog of Saccharomyces cerevisiae Mot1p) and the NC2 complex composed of NC2alpha (DRAP1) and NC2beta (Dr1) are able to bind to
TBP
directly and regulate RNA polymerase II transcription both positively and negatively. Here, we present evidence that the NC2alpha subunit interacts with BTAF1. In contrast, the NC2beta subunit is not able to associate with BTAF1 and seems to interfere with the BTAF1-
TBP
interaction. Addition of NC2alpha or the NC2 complex can stimulate the ability of BTAF1 to interact with
TBP
. This function is dependent on the presence of ATP in cell extracts but does not involve the ATPase activity of BTAF1 nor phosphorylation of NC2alpha. Together, our results constitute the first evidence of the physical cooperation between BTAF1 and NC2alpha in
TBP
regulation and provide a framework to understand transcription functions of NC2alpha and NC2beta in vivo.
...
PMID:NC2alpha interacts with BTAF1 and stimulates its ATP-dependent association with TATA-binding protein. 1550 7
MOT1
encodes an essential ATPase that functions as a general transcriptional regulator in vivo by modulating
TATA-binding protein
(
TBP
) DNA-binding activity. Although
MOT1
was originally identified both biochemically and in several genetic screens as a transcriptional repressor, a combination of subsequent genetic, chromatin immunoprecipitation, and microarray analysis suggested that
MOT1
might also have an additional role in vivo as a transcriptional activator. To better understand the role(s) of
MOT1
in vivo, we selected for genomic suppressors of a mot1 temperature-sensitive mutation. This selection identified mutations in SPT15 (
TBP
) and BUR6, both of which are clearly linked with
MOT1
at the functional level. The vast majority of the suppressor mutations, however, unexpectedly occurred in six genes that encode known components of the SUMO pathway and in two other genes with unknown functions, SLX5 and SLX8. Additional results presented here, including extensive synthetic lethality observed between slx5delta and slx8delta and SUMO pathway mutations, suggest that SLX5 and SLX8 are new components or regulators of the SUMO pathway and that SUMO modification might have a general role in transcriptional regulation as part of the
TBP
regulatory network.
...
PMID:Genetic analysis connects SLX5 and SLX8 to the SUMO pathway in Saccharomyces cerevisiae. 1638 68
Slx5 and Slx8 are heterodimeric RING domain-containing proteins that possess SUMO-targeted ubiquitin ligase (STUbL) activity in vitro. Slx5-Slx8 and its orthologs are proposed to target SUMO conjugates for ubiquitin-mediated proteolysis, but the only in vivo substrate identified to date is mammalian PML, and the physiological importance of SUMO-targeted ubiquitylation remains largely unknown. We previously identified mutations in SLX5 and SLX8 by selecting for suppressors of a temperature-sensitive allele of
MOT1
, which encodes a regulator of
TATA-binding protein
. Here, we demonstrate that Mot1 is SUMOylated in vivo and that disrupting the Slx5-Slx8 pathway by mutation of the target lysines in Mot1, by deletion of SLX5 or the ubiquitin E2 UBC4, or by inhibition of the proteosome suppresses mot1-301 mutant phenotypes and increases the stability of the Mot1-301 protein. The Mot1-301 mutant protein is targeted for proteolysis by SUMOylation to a much greater extent than wild-type Mot1, suggesting a quality control mechanism. In support of this idea, growth of Saccharomyces cerevisiae in the presence of the arginine analog canavanine results in increased SUMOylation and Slx5-Slx8-mediated degradation of wild-type Mot1. These results therefore demonstrate that Mot1 is an in vivo STUbL target in yeast and suggest a role for SUMO-targeted degradation in protein quality control.
...
PMID:Quality control of a transcriptional regulator by SUMO-targeted degradation. 1913 79
<< Previous
1
2